Home › Cystic Fibrosis › NCT03587961
Personalized Theratyping Trial
RecruitingEarly phase 1
Who can join
Ages 6 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of CF * Age ≥6 y.o. * CFTR mutation that may respond to approved correctors/potentiators in the opinion of the study investigators * Informed Consent/Assent * Stable CF pulmonary regimen Exclusion Criteria: * Exacerbation requiring antibiotic or steroids for \>28 days before trial entry * Ongoing participation in a CFTR modulator study * Active smoking in the past 6 months * History of solid organ transplant * Any condition which precludes the use of CFTR modulators: e.g. advanced cirrhosis, End-stage Renal Disease (ESRD) * Any condition that precludes the patient from participation in the opinion of the investigator * Any meds that have significant drug-drug interactions or any other off label use of CFTR modulators
About the study
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
What is being tested
- Symdeko (drug)
Sponsor: George Solomon · Participants: 20 · Started: Aug 1, 2019
Contact the study team
- Heather Hathorne, PhD · Phone: 205-638-9568
Official record on ClinicalTrials.gov — NCT03587961
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.